[go: up one dir, main page]

WO2004080372A3 - Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4) - Google Patents

Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4) Download PDF

Info

Publication number
WO2004080372A3
WO2004080372A3 PCT/EP2004/001894 EP2004001894W WO2004080372A3 WO 2004080372 A3 WO2004080372 A3 WO 2004080372A3 EP 2004001894 W EP2004001894 W EP 2004001894W WO 2004080372 A3 WO2004080372 A3 WO 2004080372A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
par4
diseases
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/001894
Other languages
English (en)
Other versions
WO2004080372A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2004080372A2 publication Critical patent/WO2004080372A2/fr
Publication of WO2004080372A3 publication Critical patent/WO2004080372A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un récepteur PAR 4 humain qui est associé aux troubles cardiovasculaires, aux troubles hormonaux et du système endocrinien, aux maladies métaboliques, gastro-intestinales et hépatiques, aux troubles hématologiques, aux troubles neurologiques, aux maladies respiratoires et aux troubles urologiques. L'invention concerne aussi des techniques permettant d'identifier des composés utiles pour traiter ou prévenir des troubles cardiovasculaires, des troubles hormonaux et du système endocrinien, des maladies métaboliques, gastro-intestinales et hépatiques, des troubles hématologiques, des troubles neurologiques, des maladies respiratoires et des troubles urologiques. L'invention concerne aussi des composés qui se lient et/ou activent ou inhibent l'activité de PAR 4, ainsi que des compositions pharmaceutiques contenant de tels composés.
PCT/EP2004/001894 2003-03-11 2004-02-26 Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4) Ceased WO2004080372A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004981 2003-03-11
EP03004981.1 2003-03-11

Publications (2)

Publication Number Publication Date
WO2004080372A2 WO2004080372A2 (fr) 2004-09-23
WO2004080372A3 true WO2004080372A3 (fr) 2005-05-12

Family

ID=32981727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001894 Ceased WO2004080372A2 (fr) 2003-03-11 2004-02-26 Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)

Country Status (1)

Country Link
WO (1) WO2004080372A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426815B2 (en) 2015-01-20 2019-10-01 The General Hospital Corporation Prevention and treatment of itch with an MRGPR antagonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043809A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Recepteur 4 active par la protease et ses utilisations
US6111075A (en) * 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
WO2001058930A1 (fr) * 2000-02-09 2001-08-16 Zymogenetics, Inc. Peptides et polypeptides de par4
WO2001060401A1 (fr) * 2000-02-17 2001-08-23 The Regents Of The University Of California Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g
WO2001094411A1 (fr) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulant des recepteurs actives par des recepteurs de protease et methodes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043809A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Recepteur 4 active par la protease et ses utilisations
US6111075A (en) * 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
WO2001058930A1 (fr) * 2000-02-09 2001-08-16 Zymogenetics, Inc. Peptides et polypeptides de par4
WO2001060401A1 (fr) * 2000-02-17 2001-08-23 The Regents Of The University Of California Methodes de modulation de l'activation du recepteur 4 active par des proteases (par4) avec de la cathepsine g
WO2001094411A1 (fr) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulant des recepteurs actives par des recepteurs de protease et methodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU W.-F. ET AL.: "Cloning and characterization of human protease-activated receptor 4.", PROC. NATL. ACAD. SCI. USA, vol. 95, June 1998 (1998-06-01), pages 6642 - 6646, XP002112286 *

Also Published As

Publication number Publication date
WO2004080372A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2004086034A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2004080372A3 (fr) Diagnostic et traitement de maladies associees au recepteur 4 active par la proteinase et couple aux proteines g (par 4)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2005059504A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g gpr34 (gpr34)
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2004099772A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur agtr1a couple aux proteines g (agtr1a)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005003779A3 (fr) Diagnostics et traitements therapeutiques des maladies associees au recepteur 3 couple a une proteine g specifique aux neurones sensoriels (snsr3)
WO2004086047A3 (fr) Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1)
WO2004082572A3 (fr) Diagnostics et therapies pour les maladies associees au recepteur 87 couple a la proteine g (gpr87)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase